Dr. Rasi concluded, ``Maintenance of a constant level of thymosin alpha 1 in the circulation seems to further increase its immunological effects. Moreover, this dosage regimen leads to effects on granulocytes as well as monocytes. This suggests new possibilities to use this compound in anticancer strategies.''
``This study shows that ZADAXIN, when administered through continuous infusion, has a stronger effect on countering the immune system side effects of anti-cancer chemotherapy and a broader effect on the immune system through impressive actions we are just now identifying,'' commented Dr. Alfred Rudolph, M.D., SciClone's Chief Operating Officer. ``We are excited by the new possibilities for ZADAXIN with this new delivery method.''
ZADAXIN has been administered without side effects to over 10,000 patients and is approved for sale in 26 countries, principally for the treatment of hepatitis B and hepatitis C, and certain cancers. ZADAXIN, an immune system enhancer (ISE), is a synthetic preparation of a natural peptide, thymosin alpha 1, that enhances the body's Th1 immune response to serious viral infections and certain cancers.
SciClone develops and commercializes pharmaceutical and biological therapeutic compounds that are acquired or in-licensed at the stage of late pre-clinical or early clinical development. SciClone's strategic goal, based on the broad therapeutic potential of its lead drug ZADAXIN, is to become the preeminent worldwide provider of immune system enhancers as monotherapies and as critical components of combination drug therapies for infectious diseases and cancer. Other drugs in SciClone's pipeline are intended to protect and expand this franchise, and to address the protein-based disorder that causes cystic fibrosis.